Oxford BioMedica plc Rating Reiterated by N+1 Singer (OXB)
Oxford BioMedica plc (LON:OXB)‘s stock had its “buy” rating reiterated by research analysts at N+1 Singer in a report released on Thursday. They currently have a GBX 3.30 ($0.05) target price on the stock. N+1 Singer’s price target would indicate a potential downside of 6.25% from the company’s current price.
Oxford BioMedica plc (LON:OXB) traded down 12.00% during mid-day trading on Thursday, hitting GBX 3.30. 3,270,663 shares of the company’s stock traded hands. Oxford BioMedica plc has a 52 week low of GBX 1.551 and a 52 week high of GBX 3.80. The stock has a 50-day moving average of GBX 3.03 and a 200-day moving average of GBX 2.61. The company’s market cap is £46.7 million.
Separately, analysts at Oriel Securities Ltd reiterated an “add” rating on shares of Oxford BioMedica plc in a research note on Wednesday, June 18th.
Oxford BioMedica plc (LON:OXB) is a biopharmaceutical company developing gene-based medicines and therapeutic vaccines.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with Analyst Ratings Network's FREE daily email newsletter.